CMS Final Rule Ends Federal Medicaid and CHIP Funding for Gender-Affirming Care for Transgender Minors

What Happened

On August 11, 2026, the Centers for Medicare & Medicaid Services (CMS) released a final rule that ends federal Medicaid and Children's Health Insurance Program (CHIP) payment for what the agency calls "sex-rejecting procedures" for minors. CMS defines the term as "a pharmaceutical or surgical intervention undertaken for the purpose of aligning an individual's physical appearance or body with an asserted identity that differs from the individual's sex assigned at birth" — in practice, puberty blockers, cross-sex hormone therapy and transition-related surgery. The bar applies to Medicaid beneficiaries under 18 and CHIP enrollees under 19.

The rule is targeted by purpose rather than by treatment. According to a McGuireWoods analysis of the final rule, the same interventions remain federally reimbursable for disorders of sexual development and other non-transition uses, with central precocious puberty and growth-hormone deficiency cited as examples. Minors already receiving cross-sex hormone therapy when the rule takes effect receive up to six months of continued federally funded coverage. States remain free to pay for the care using only state money.

AJMC reported that roughly 17 states covered one or more of these services in Medicaid and that CMS projected about $138 million in reduced federal spending over fiscal years 2027–2036. HHS Secretary Robert F. Kennedy Jr. said the federal government "will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve," and CMS Administrator Mehmet Oz said that "by cutting off federal funds for these sex-rejecting procedures, we're following the science." A separate proposed rule that would use hospital Conditions of Participation to restrict the same care had not been finalized.

The Legal Challenge

On September 2, 2026, attorneys general from 20 states and the District of Columbia, joined by Pennsylvania Gov. Josh Shapiro, filed suit in federal court in Massachusetts. The coalition — California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Nevada, New Jersey, New York, Oregon, Rhode Island, Vermont, Virginia, Washington and Wisconsin — argues that CMS has no authority under the Medicaid statute to categorically exclude lawful, medically necessary treatments from reimbursement, that the rule violates the Administrative Procedure Act, and that it intrudes on the states' role as Medicaid administrators in violation of the Spending Clause. Vermont's attorney general said the rule prohibits reimbursement for care for transgender youth "while covering the same health care treatment when provided to non-transgender youth." New York Attorney General Letitia James said: "The federal government does not have the authority to dictate what medically necessary care New York provides to its residents."

Legal Analysis

The rule's operative feature is that it withholds federal funding for a drug or procedure only when it is prescribed to a transgender minor for gender transition, while continuing to pay for the identical drug or procedure for other children. Domestically, the primary questions are statutory and procedural — whether the Medicaid Act permits CMS to carve a category of otherwise-covered, physician-prescribed care out of federal financial participation, and whether the agency's reasoning survives arbitrary-and-capricious review. Those questions are now before the District of Massachusetts.

Internationally, purpose-based exclusions that turn on a patient's gender identity implicate the non-discrimination and equal-protection guarantees of Articles 2 and 26 of the ICCPR, which UN treaty bodies have read to cover gender identity. The Convention on the Rights of the Child, which the United States has signed but not ratified, recognizes every child's right to the highest attainable standard of health.

Why This Entry Is Rated Severe

The rule removes federal funding for ongoing medical treatment from an identifiable, low-income population of minors who depend on public insurance, and it does so by a criterion — transgender status — that the rule itself makes explicit by preserving coverage of the same treatments for other children. The harm is concentrated on families with the fewest alternatives: those who cannot pay privately and who live in states that will not replace federal dollars with their own. The rating is limited to "severe" rather than higher because states may continue to fund the care, because the rule provides a six-month tapering period, and because the rule's legality is under active judicial review.